Table 2.
CYP2C9 genotyping results in patients with acute gastrointestinal bleeding secondary to NSAID and in control individuals who reported no adverse effects during NSAID therapy
| Genotype | Bleeding patients num, (%) | Control patients num, (%) | Crude OR | 95% CI | P |
|---|---|---|---|---|---|
| CYP2C9*1/*1 | 43 (45.7) | 74 (59.7) | 0.57 | 0.32–1.02 | 0.041 |
| CYP2C9*1/*2 | 30 (31.9) | 29 (23.4) | 1.54 | 0.81–2.93 | 0.161 |
| CYP2C9*1/*3 | 12 (12.7) | 16 (12.9) | 0.99 | 0.41–2.35 | 0.976 |
| CYP2C9*2/*2 | 6 (6.4) | 2 (1.6) | 4.16 | 0.74–30.6 | 0.078a |
| CYP2C9*2/*3 | 2 (2.1) | 1 (0.8) | 2.67 | 0.19–75.7 | 0.579a |
| CYP2C9*3/*3 | 1 (1.1) | 2 (1.6) | 0.66 | 0.02–9.39 | 0.731a |
| Total | 94 (100) | 124 (100) | – | – | – |
a
Fisher's test was used for these comparisons.